Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
IDYA

IDYA - Ideaya Biosciences Inc Stock Price, Fair Value and News

38.27USD-0.66 (-1.70%)Delayed as of 14 Jun 2024, 11:03 am ET

Market Summary

IDYA
USD38.27-0.66
Delayedas of 14 Jun 2024, 11:03 am
-1.70%

IDYA Alerts

  • 2 major insider sales recently.

IDYA Stock Price

View Fullscreen

IDYA RSI Chart

IDYA Valuation

Market Cap

2.9B

Price/Earnings (Trailing)

-22.86

Price/Sales (Trailing)

126

Price/Free Cashflow

-21.85

IDYA Price/Sales (Trailing)

IDYA Profitability

Return on Equity

-13.78%

Return on Assets

-13.41%

Free Cashflow Yield

-4.58%

IDYA Fundamentals

IDYA Revenue

Revenue (TTM)

23.4M

Rev. Growth (Yr)

-2.47%

Rev. Growth (Qtr)

-51.2%

IDYA Earnings

Earnings (TTM)

-128.9M

Earnings Growth (Yr)

-67.39%

Earnings Growth (Qtr)

-16.54%

Breaking Down IDYA Revenue

52 Week Range

20.9038.86
(Low)(High)

Last 7 days

-1.8%

Last 30 days

-6.9%

Last 90 days

-12.1%

Trailing 12 Months

56.7%

How does IDYA drawdown profile look like?

IDYA Financial Health

Current Ratio

28.42

IDYA Investor Care

Shares Dilution (1Y)

56.47%

Diluted EPS (TTM)

-2.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
202347.5M45.1M23.5M23.4M
202232.1M29.1M49.9M50.9M
202121.6M23.7M25.8M27.9M
202000019.5M

Tracking the Latest Insider Buys and Sells of Ideaya Biosciences Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 29, 2024
white michael anthony
acquired
366,510
12.86
28,500
chief scientific officer
May 29, 2024
white michael anthony
sold
-1,032,880
36.2416
-28,500
chief scientific officer
May 16, 2024
hata yujiro s
acquired
148,406
4.31
34,433
president and ceo
May 16, 2024
hata yujiro s
sold
-1,439,750
41.8132
-34,433
president and ceo
May 15, 2024
hata yujiro s
acquired
361,419
4.31
83,856
president and ceo
May 15, 2024
hata yujiro s
sold
-3,597,760
42.904
-83,856
president and ceo

1–10 of 50

Which funds bought or sold IDYA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
372,000
2,128,000
-%
May 29, 2024
Opaleye Management Inc.
sold off
-100
-11,083,200
-
-%
May 28, 2024
Boston Partners
new
-
587,600
587,600
-%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
new
-
219,400
219,400
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
92.5
364,546
629,546
0.08%
May 20, 2024
Virtu Financial LLC
sold off
-100
-582,000
-
-%
May 16, 2024
COMERICA BANK
added
723
59,580
66,091
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-27.44
-153,437
1,306,660
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
18.97
804,023
2,524,640
-%
May 15, 2024
AQR CAPITAL MANAGEMENT LLC
added
6.4
176,422
741,397
-%

1–10 of 49

Are Funds Buying or Selling IDYA?

Are funds buying IDYA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own IDYA
No. of Funds

Unveiling Ideaya Biosciences Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
price t rowe associates inc /md/
5.5%
3,568,938
SC 13G
Feb 14, 2024
biotechnology value fund l p
2.8%
1,804,865
SC 13G/A
Feb 14, 2024
avidity partners management lp
2.4%
1,520,000
SC 13G/A
Feb 14, 2024
janus henderson group plc
5.5%
3,551,891
SC 13G
Feb 13, 2024
logos global management lp
2.8%
1,800,000
SC 13G/A
Feb 13, 2024
vanguard group inc
5.39%
3,475,772
SC 13G
Feb 12, 2024
fmr llc
-
0
SC 13G
Feb 07, 2024
adage capital partners gp, l.l.c.
4.54%
2,925,094
SC 13G/A
Feb 01, 2024
canaan x l.p.
2.4%
1,570,820
SC 13G/A
Jan 25, 2024
blackrock inc.
8.4%
5,436,668
SC 13G/A

Recent SEC filings of Ideaya Biosciences Inc

View All Filings
Date Filed Form Type Document
Jun 03, 2024
8-K
Current Report
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
8-K
Current Report

Peers (Alternatives to Ideaya Biosciences Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
55.6B
6.8B
13.11% 15.14%
-9.32
8.12
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.2B
2.0B
8.19% -19.39%
-60.96
10.11
75.20% 68.82%
16.0B
2.5B
5.74% -10.79%
77.85
6.47
13.74% 186.89%
14.1B
3.8B
9.90% 2.05%
18.88
3.74
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.17% 71.70%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
3.28% -53.81%
-12.38
9.86
394.93% 39.61%
3.4B
251.0M
-6.27% -10.41%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
15.67% -25.01%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.62% -37.45%
-1.5K
3.06
56.43% 98.83%
2.1B
996.6M
11.65% 94.95%
-5.3
2.12
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-7.16% 29.42%
27.77
4.4
60.38% -34.49%
564.4M
881.7K
22.84% 567.64%
-16.72
481.06
-77.61% 33.36%
244.6M
4.2M
-17.34% 57.33%
-1.96
58.8
-66.30% 48.24%
22.1M
2.1M
36.17% 271.01%
-0.95
7.61
-13.45% 69.54%

Ideaya Biosciences Inc News

Latest updates
Defense World23 hours ago
Investing.com Nigeria01 Jun 202406:00 am

Ideaya Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q3
Revenue-100.0%-3,9238,0383,5447,8804,02229,6995,85111,3592,9628,9768,7567,2478,1078,967
Operating Expenses11.3%51,01745,83941,56436,25334,15930,46529,03928,35025,57921,33120,68919,80716,38215,85113,963
  S&GA Expenses16.2%8,2127,0697,8637,0756,3005,7536,6675,5545,9235,2215,1864,8284,8163,8003,938
  R&D Expenses10.4%42,80538,77033,70129,17827,85924,71322,37222,79619,65616,11015,50314,97911,56612,05110,025
Interest Expenses-62.5%12.0032.0011.0013.0013.0014.0014.0016.0016.0016.0018.0018.0019.0020.0020.00
Income Taxes----------------
Net Income-16.5%-39,572-33,955-27,440-27,926-23,640-24,2011,615-22,056-14,013-18,212-11,582-10,947-9,021-5,135-4,926
Net Income Margin-14.1%-5.51*-4.83*-4.39*-1.64*-1.44*-1.15*-1.06*-2.26*-1.71*-1.78*-1.42*-1.26*-1.45*--
Free Cashflow-83.6%-45,138-24,586-30,777-34,344-27,885-23,370-25,267-21,933-20,048-17,262-12,926-13,508-14,727--
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q4
Assets48.1%96264953352836538841133835938139932832629830118510211312213397.00
  Current Assets33.2%70953348250234437039327225625126928030828928117489.0010211212391.00
    Cash Equivalents-31.0%10815715210367.0069.0010249.0055.0092.0010890.0013772.0081.0014835.0034.0039.0088.0021.00
  Net PPE12.1%7.006.006.007.007.007.007.007.005.005.005.005.005.004.004.004.004.005.005.005.005.00
Liabilities-7.1%26.0028.0025.0026.0031.0039.0042.0069.0070.0080.0082.0088.0093.0010010612.0013.0013.0012.0013.007.00
  Current Liabilities-7.9%25.0027.0025.0025.0030.0032.0033.0058.0057.0045.0039.0036.0036.0039.0054.007.007.007.006.006.005.00
Shareholder's Equity50.6%93562150850233434936926928930231824023319819517289.00100110121-
  Retained Earnings-11.3%-387-348-314-287-259-235-211-212-190-176-158-146-136-126-121-116-104-92.49-81.71-70.74-50.52
  Additional Paid-In Capital36.7%1,3249698237905945885844864824794763873693253172891941931921912.00
Shares Outstanding15.0%75.0065.0059.0057.0048.0048.0039.0039.0039.0035.0034.0033.00---------
Float----1,300---493---629---343---135-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-84.5%-43,813-23,748-30,174-33,460-27,842-23,370-24,166-19,992-19,647-16,657-12,468-12,930-13,724-11,59690,210-13,606-9,545-8,706-10,550-10,272-9,785
  Share Based Compensation31.6%6,3124,7985,3014,7313,6592,9753,0053,0442,6052,0642,1972,0581,9181,046981824758719518548383
Cashflow From Investing-216.2%-353,971-111,94351,347-121,38123,521-10,276-18,68313,316-17,761-413-56,307-49,38136,435-4,554-183,58330,98810,9063,887-38,44111,41125,408
Cashflow From Financing147.8%349,111140,89427,834191,0632,92632495,69749165368886,77615,98642,0046,94927,06894,69934.0038.00-27651,674-826
  Buy Backs-------------------2.002.00--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

IDYA Income Statement

2024-03-31
Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Collaboration revenue$ 0$ 7,880
Operating expenses  
Research and development42,80527,859
General and administrative8,2126,300
Total operating expenses51,01734,159
Loss from operations(51,017)(26,279)
Interest income and other income, net11,4452,639
Net loss(39,572)(23,640)
Unrealized (losses) gains on marketable securities(1,485)1,466
Comprehensive loss$ (41,057)$ (22,174)
Net loss per common share, basic$ (0.53)$ (0.49)
Net loss per common share, diluted$ (0.53)$ (0.49)
Weighted-average common shares outstanding, basic75,108,48448,370,074
Weighted-average common shares outstanding, diluted75,108,48448,370,074

IDYA Balance Sheet

2024-03-31
Condensed Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets  
Cash and cash equivalents$ 108,345$ 157,018
Short-term marketable securities590,427368,096
Accounts receivable1518
Prepaid expenses and other current assets10,5667,500
Total current assets709,353532,632
Restricted cash757757
Long-term marketable securities242,636107,492
Property and equipment, net6,9096,164
Right-of-use assets1,7802,246
Other non-current assets9225
Total assets961,527649,316
Current liabilities  
Accounts payable6,2906,598
Accrued liabilities17,51918,756
Operating lease liabilities - current1,1511,747
Total current liabilities24,96027,101
Long-term operating lease liabilities1,2561,125
Total liabilities26,21628,226
Commitments and contingencies (Note 6)
Stockholders’ equity  
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and December 31, 2023
Common stock, $0.0001 par value, 300,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 74,764,628 and 65,039,369 shares issued and outstanding as of March 31, 2024 and December 31, 202377
Additional paid-in capital1,324,163968,885
Accumulated other comprehensive (loss) income(923)562
Accumulated deficit(387,936)(348,364)
Total stockholders’ equity935,311621,090
Total liabilities and stockholders’ equity$ 961,527$ 649,316
IDYA
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase II clinical trial for patients with solid tumors having methylthioadenosine phosphorylase gene deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester todevelop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase II/III study in metastatic uveal melanoma, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEideayabio.com
 INDUSTRYBiotechnology
 EMPLOYEES116

Ideaya Biosciences Inc Frequently Asked Questions


What is the ticker symbol for Ideaya Biosciences Inc? What does IDYA stand for in stocks?

IDYA is the stock ticker symbol of Ideaya Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ideaya Biosciences Inc (IDYA)?

As of Thu Jun 13 2024, market cap of Ideaya Biosciences Inc is 2.95 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IDYA stock?

You can check IDYA's fair value in chart for subscribers.

What is the fair value of IDYA stock?

You can check IDYA's fair value in chart for subscribers. The fair value of Ideaya Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ideaya Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IDYA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ideaya Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether IDYA is over valued or under valued. Whether Ideaya Biosciences Inc is cheap or expensive depends on the assumptions which impact Ideaya Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IDYA.

What is Ideaya Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, IDYA's PE ratio (Price to Earnings) is -22.86 and Price to Sales (PS) ratio is 126. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IDYA PE ratio will change depending on the future growth rate expectations of investors.